Medical Education/Degrees

1992 –1998    MD (1998) Yerevan State Medical University Named after Mkhitar Heratsi, Armenia

2003 –2009    PhD (2009) Russian Academy of Medical Science, Burdenko Neurosurgery Institute, Russian Federation

Licenses/Certifications

Certificate of Neurosurgery. Russian Academy of Postgraduate Education (2020).

License of Practicing  in Neurosurgery. Russian Academy of Postgraduate Education (2012).

License of Practicing in Neurosurgery. Russian Academy of Postgraduate Education (2009).

Medical Work Experience

08/2020 – Present    Astghik Medical Center, Yerevan, Armenia, Neurosurgeon

10/2019 – Present     Arabkir Medical Center, Yerevan, Armenia, Neurosurgeon

02/2013 –11/2014    Arabkir Medical Center, Yerevan, Armenia, Neurosurgeon

06/2011 –06/2012  City Clinical Hospital N15, Moscow, Russian Federation, Neurosurgeon

01/2010 –06/2012  City Clinical Hospital N67, Moscow, Russian Federation, Neurosurgeon

Medical Training

04/2014 – 07/2014      Neurosurgery International Fellowship granted by WFNS, NYU Langone Medical Center, NY, USA

04/2003 – 09/2008     Burdenko Neurosurgery Institute, Department of Pediatric Neurosurgery, Moscow, Russian Federation/PhD student (aspirantura) 

10/1998 –09/2001    National Institute of Health, Yerevan, Armenia, Neurosurgery Residency

Research Training and Work Experience

07/2018–08/2019    Cedars-Sinai Medical Center, Nanomedicine Center, Neurosurgery Department, Los Angeles, USA, Project Scientist

11/2014–07/2018    Cedars-Sinai Medical Center, Nanomedicine Center, Neurosurgery Department, Los Angeles, USA, Postdoctoral Research Scientist

07/2014  Mount Sinai School of Medicine, Dr. Zou Laboratory, NY, USA. Volunteer Researcher

Co-investigator in the research projects:

Nano-immunoconjugates delivery to the brain and checkpoint inhibitors for treatment of glioblastoma.

Air pollution and brain tumors. Influence of different kind of particles and exposure time on tumorogenesis, brain inflammation, and degenerative diseases.

New approaches for the treatment of primary and metastatic cancer using checkpoint and molecular inhibitors.

Nanotherapeutics in brain lymphoma treatment.

Nanoconjugates delivery for imaging and treatment of Alzheimer’s disease.

Differential MRI imaging for brain tumor metastases using different molecular targeting nanodrugs.

Image-guided surgery and treatment of gliomas.

Grants participation

1.    NIH R01 CA188743. “Differential Nano MRI imaging for brain tumor metastases diagnosis and treatment monitoring”. 04/01/2015-03/31/2020. PI: LJUBIMOVA

2.    NIH/NCI R01 CA206220-01. “Nanoconjugates delivery of proliferation and checkpoint inhibitors”. 05/01/2016-04/30/2021. PI: LJUBIMOVA

3.    NIH/NCI 1R01 CA 209921-01. 07/01/2016-06/30/2021. “Glial tumor image-guided surgery and treatment”. PI: HOLLER

4.    Brain Tumor and Air Pollution Foundation Grant RFP BLTAP-1“Study the effect of air pollution chronic exposure at stem cells activation in the brain”. 04/01/16-03/31/18. PI: BLACK

5.    Brain Tumor and Air Pollution Foundation Grant “AQMD grant RFP#PBOC-9 2012 Role of particle-induced inflammation on progression of neurodegenerative brain diseases”. 07/01/17-06/30/18. PI: BLACK

Co-investigator in clinical  trials:

2005 –2008    International Infant Hydrocephalus  Study (IIHstudy): Multicenter Prospective Randomized Study of Endoscopic Third Ventriculostomy vs VP-Shunting in children under the age of 2 years with pure aqueduct stenosis. Burdenko Neurosurgery Institute, Moscow, Russian Federation.

 
Publications:
1.    Single- and Multi-Arm Gadolinium MRI Contrast Agents for Targeted Imaging of Glioblastoma. Patil R, Galstyan A, Grodzinski ZB, Shatalova ES, Wagner S, Israel LL, Ding H, Black KL, Ljubimova JY, Holler E.Int J Nanomedicine. 2020 May 1;15:3057-3070. 
2.    Israel LL, Galstyan A, Holler E, Ljubimova JY. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. J Control Release. 2020 Apr 10;320:45-62.
3.    Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY. Blood-brain barrier permeable nano immunocomjugates induce local immune responses for glioma therapy. Nat Commun. 2019 Aug 28;10(1):3850
4.    AraՕjo JE, Jorge S, Santos HM, Chiechi A, Galstyan A, Lodeiro C, Diniz M, Kleinman MT, Ljubimova JY, Capelo JL. Proteomic changes driven by urban pollution suggest particulate matter as a deregulator of energy metabolism, mitochondrial activity, and oxidative pathways in the rat brain. Sci Total Environ. 2019 Oct 15;687:839-848
5.    Patil R, Galstyan A, Sun T, Shatalova ES, Butte P, Mamelak AN, Carico C, Kittle DS, Grodzinski ZB, Chiechi A, Ding H, Black KL, Ljubimova JY, Holler E. Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme. Biomaterials. 2019 Jun; 206:146-159
6.    Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, Rudnick JD, Hu J, Grodzinski ZB, Rekechenetskiy A, Falahatian V, Lyubimov AV, Chen YL, Leoh LS, Daniels-Wells TR, Penichet ML, Holler E, Ljubimov AV, Black KL, Ljubimova JY. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. Cancer Res. 2019 Mar 15;79(6):1239-1251
7.    Israel LL, Braubach O, Galstyan A, Chiechi A, Shatalova ES, Grodzinski Z, Ding H, Black KL, Ljubimova JY, Holler E.A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier. ACS Nano. 2019 Feb 26; 13(2):1253-1271
8.    Ljubimova JY, Braubach O, Patil R, Chiechi A, Tang J, Galstyan A, Shatalova ES, Kleinman MT, Black KL, Holler E. Coarse particulate matter (PM2.5-10) in Los Angeles Basin air induces expression of inflammation and cancer biomarkers in rat brains. Sci Rep. 2018 Apr 9;8(1):5708
9.    Ding H, Fox I, Patil R, Galstyan A, Black KL, Ljubimova JY, and Holler E. “Polymalic acid tritryptophan copolymer interacts with lipid membrane resulting in membrane solubilization”. Journal of Nanomaterials, 2017
10.    Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, Ljubimov AV, Ljubimova JY. "Simultaneous blockade of CK2 and EGFR pathways by tumor-targeted nanobioconjugates significantly improves therapeutic efficacy against glioblastoma multiforme”. Journal of Controlled Release, 244 (2016) 14-23.
11.    Ding H, Gangalum PR, Galstyan A, Fox I, Patil R, Hubbard P, Murali R, Ljubimova JY, Holler E. “HER2-positive breast cancer targeting and treatment by a 2 peptide-conjugated mini nanodrug”. Nanomedicine: Nanotechnology, Biology, and Medicine, pii: S1549-9634(16)30103-4. 2016 Aug
12.    Galstyan AG, Melikian AG, Korshunov AE, Arutyunov NV. “Endoscopic ventriculostomy of the third ventricle in infants of less than 2 years of age”.  Zh Vopr Neirokhir Im N.N. Burdenko. (1):11-6; discussion 16-7. Russia, Jan-Mar 2008.

Abstracts, Presentations and Poster Sessions:

1.    Israel L.L., Braubach O., Galstyan A., Chiechi A., Shatalova S. E., Grodzinski Z., Ding H., Holler E, Black L.K., Ljubimova Y.J. Biodegradable polymalic acid conjugated to Angiopep-2 and tri-leucine traverses the blood-brain barrier and distributes throughout the mouse brain. In Controlled release society (CRS) Annual meeting & Exposition New York city, NY, USA, 2018. (Poster and oral presentation)
2.    Patil R, Galstyan A, Wagner S, Sun T, Chechi A, Shatalova E, Grodzinski Z, Ding H, Black KL, Holler E, Ljubimova JY. MRI Virtual Biopsy and Treatment of Brain Metastatic Tumors by BBB Crossing Nanoconjugates. Research Day IX, Cedars-Sinai Medical Center, February 19, 2018, Los Angeles, CA, USA. (Poster)
3.    Patil R, Galstyan A, Sun T, Shatalova E, Butte P, Carico C,  Chechi A, Mamelak A, Kittle D, Braubach O, Israel L, Ding H, Black KL, Ljubimova JY, Holler E. Targeted Nano Agent for Fluorescence Guided Resection of Glioblastoma. Research Day IX, Cedars-Sinai Medical Center, February 19, 2018, Los Angeles, CA, USA. (Poster)
4.    Holler E, Israel L, Braubach O, Patil R, Ding H, Murali R, Galstyan A, Sun T, Ljubimova JY. Borderline sized nano drugs for efficient targeting and delivery through multi bio barriers. Research Day IX, Cedars-Sinai Medical Center, February 19, 2018, Los Angeles, CA, USA. (Poster)
5.    Ljubimova JY, Chiechi A, Galstyan A, Shatalova E, Sun T, Grodzinski Z, Ljubimov AV, Black KL, Holler E, Ding H. Nano immunotherapeutics crossing BBB for delivery of checkpoint inhibitors and activation of local brain tumor immune systems for glioma treatment. Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy. Feb. 12-15, 2018, San Diego, CA, USA.
6.    Ljubimov VA, Galstyan A, Chou ST, Patil R, PhD, Ding H, Prasad RS, Holler E, Ljubimova JY, Black KL, Ljubimov AV. Double blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiform., AACR Annual Meeting, March 31- April 5, 2017, Washington DC, USA. Available online at: #191, http://www.aacr.org/Documents/AACR2017_Proceedings.pdf 
7.    Ljubimova JY, Ljubimov VA, Patil R, Falahatian V, Ding H, Galstyan A, Holler E, Black KL. In vivo targeting of laminin-411–β1 integrin-Notch signaling pathway using nanobioconjugate alters glioma microenvironment for effective treatment. AACR Annual Meeting, March 31- April 5, 2017, Washington DC, USA. Available online at: #5938, http://www.aacr.org/Documents/AACR2017_Proceedings.pdf 
8.    Ljubimov VA, Galstyan A, Chou ST, Patil R, Ding H, Prasad RS, Holler E, Ljubimova JY, Black KL, Ljubimov AV. Blockade of CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiform. AANS Annual Scientific Meeting, Neurosurgery: A World of Innovation, April 22-26, 2017, Los Angeles, USA. Available online at: #1976, https://aans.eventsential.org/Sessions/Details/269507
9.    Ljubimov VA, Patil R, Galstyan A, Prasad RS, Ding H, Holler E, Ljubimova JY, Black KL. Nanoclinic in the Brain. Nanoconjugates for MRI Virtual Biopsy and Treatment of Brain Metastatic Tumors. AANS Annual Scientific Meeting, Neurosurgery: A World of Innovation. April 22-26, 2017, Los Angeles, USA. Available online at: #648, http://thejns.org/doi/abs/10.3171/2017.4.JNS.AANS2017abstracts
10.    Ljubimova JY, Ljubimov VA, Patil R, Falahatian V, Ding H, Galstyan A, Holler E, Black KL.  Nanobioconjugate for targeting of laminin-411–Notch signaling alters glioma microenvironment for tumor growth suppression. AANS Annual Scientific Meeting, Neurosurgery: A World of Innovation, April 22-26, 2017, Los Angeles, USA. Available online at: #833, http://thejns.org/doi/abs/10.3171/2017.4.JNS.AANS2017abstracts
11.    Patil R, Ding H, Chou ST, Galstyan A, Gungallum PR, Ljubimov VA, Black KL, Holler H, Ljubimov AV, Ljubimova JY. Nanobioconjugates crossing multiple biobarriers regulate laminin-411–Notch signaling pathways and change glioma microenvironment suppressing tumor growth. Mechanisms and Barriers in Nanomedicine Workshop. July 15-16, 2016, Beaver Run Resort, Breckenridge, Colorado, USA.
12.    Nanobiopolymer targeting of laminin-411–Notch signaling pathway changes glioma microenvironment for tumor growth suppression. Ljubimova J.Y., Patil R., Galstyan A., Sun T., Ding H., Black K.L.and Holler E.. Controlled Release Society Annual Meeting & Exposition, July 16-19 2017, Boston, USA. (Poster).
13.    Investigation of the lipid membrane solubilization as a result of interaction with polymalic acid tritryptophan copolymer, Controlled Release Society Annual Meeting & Exposition. Ding H., Fox I., R. Patil, Galstyan A., K.L. Black, Ljubimova J.Y. and Holler E.. July 16-19 2017, Boston, USA. (Poster).
14.    Next Generation: Mini Nano Drug, Controlled Release Society Annual Meeting & Exposition. Holler E., Ding H., Gangalum P., Galstyan A., Patil R., Hubbard P., Murali R., Black K.L., and Ljubimova J.Y. July 16-19 2017, Boston, USA. (Poster).
15.    Nanoconjugates development for MRI virtual biopsy and treatment of brain metastatic tumors via multiple specific targets. Patil R., Galstyan A., Ding H., Black K.L., Holler E. and Ljubimova J.Y.. Controlled Release Society Annual Meeting & Exposition, July 16-19 2017, Boston, USA. (Poster).
16.    Development of a fluorescent nano agent for image-guided resection of glioblastoma in preclinical mouse. Patil R., Butte P., Mamelak A., Carico C., Kittle D.S., Galstyan A., Ding H., Black K.L., Ljubimova J.Y., Holler E. World Molecular Imaging Society, Sept 13-16 2017, Philadelphia USA. (Poster).
17.    Gangalum PR, Ljubimov AV, Chesnokova A, Patil R, Ding H, Portilla-Arias J, Chou ST, Galstyan A, Mamelak A, Bannykh S, Phuphanich S, Rudnick J, Hu J, Patil C, Holler H, Black KL, Ljubimova JY. Nanobioconjugates crossing multiple biobarriers regulate laminin-411 – Notch signaling pathways and change glioma microenvironment by suppressing the tumor growth. BioBarriers 2016. March 7, 2016. Saarbruecken, Germany.
18.    Ljubimova JY, Gangalum P, Holler E, Portilla-Aries J, Patil R, Ding H, Kleinman MT, Mashouf L, Fox I, Galstyan A, Chou Szu-Ting, Black KL. PL3 – Genomic/proteomic changes in rat brain after acute and chronic exposures to particulate matter in Los Angeles basin air: Comparison with human brain tumors. PTIM 2015 1st International Caparica Conference on Pollutant Toxic Ions and Molecules, November 2015, Portugal.
19.    Melikian A, Korshunov A, Galstyan A, Arutyunov N. Large anterior fontanel predicts failure of endoscopic third ventriculostomy ininfants. Neuroendoscopy International Conference. May 2007, Versailles, France.
20.    Galstyan A, Korshunov A, Arutyunov N, MelikianA. Endoscopic ventriculostomy III ventricle (ETV) in children younger than 2 years. 115th meeting of the Moscow Society of Neurological Surgeons. June 2008, Moscow, Russia.
21.    Galstyan A. Evaluation of the results of ETV for children under 2 years old. “Polenovskie Chteniya” Annual Meeting’s Abstracts, p. 250. 2006, Sankt-Petersburg, Russia.
22.    Melikian A, Galstyan A, Arutyunov N. Endoscopic third ventriculostomy in treatment of occlusive hydrocephalus for children under 2 years old. 4th Congress of Russian Neurosurgeons. June 2006, Moscow, Russia.

Language Fluency
Armenian, Russian, English, French